The recent pullback in Novo Nordisk stock after its guidance update has put a harsh spotlight on obesity and metabolic disorder therapeutics. The market reaction underscored how sensitive investors are to clinical data, pipeline clarity, and competitive pressure from Eli Lilly’s obesity drugs. For you, this creates a chance to reassess exposure to companies tied to the same theme. This article looks at three stocks from our Healthcare, Obesity and Metabolic Disorder Therapeutics screener that are closely connected to the Novo Nordisk news. Each one appears to be positioned to reflect the current debate around obesity drug growth and competition.

BioMarin Pharmaceutical (BMRN)

Overview: BioMarin Pharmaceutical develops and sells treatments for rare genetic and metabolic conditions, with a portfolio that includes enzyme replacement therapies like VIMIZIM and NAGLAZYME, growth disorder treatment VOXZOGO, and other drugs targeting small but often severe patient populations worldwide.

Operations: BioMarin generates about US$3.2b from developing and commercializing therapies, with revenue spread across the United States (about US$1.1b), Europe (about US$864m), Latin America (about US$455m), the Rest of World (about US$572m) and around US$196m unallocated.

Market Cap: US$11.6b

BioMarin Pharmaceutical sits at the crossroads of rare disease and metabolic disorder treatment, which makes it relevant as investors reassess obesity and growth disorder therapies after the Novo Nordisk update. The company already earns multi billion dollar revenue from approved products and is pushing VOXZOGO into hypochondroplasia, with Phase 3 data meeting its main goal and an FDA filing planned this year. At the same time, the story is not risk free. Earnings have been affected by a one off loss, margins have compressed, and competition around growth therapies is building, all of which could limit how much of the potential is realized. The key issue is how these moving pieces affect the long term opportunity investors are trying to price in today.

BioMarin Pharmaceutical’s rare disease engine and VOXZOGO expansion story can look compelling, yet the compressed margins and one off earnings loss raise tougher questions. Get the full picture with the 2 key rewards and 2 important warning signs

Ligand Pharmaceuticals (LGND)

Overview: Ligand Pharmaceuticals develops and licenses a wide range of biopharmaceutical assets, collecting royalties and fees on drugs for infectious disease, cancer, kidney and liver conditions, metabolic and rare diseases, and other areas, rather than relying on a single flagship product. This model gives you exposure to treatments like VEKLURY for COVID-19, FILSPARI for kidney disease, and a pipeline of partnered programs without Ligand carrying full development and commercialization risk.

Operations: Ligand generates about US$274.5m from developing and licensing biopharmaceutical assets, with all reported revenue coming from the United States.

Market Cap: US$5.8b

Ligand Pharmaceuticals is attracting attention because its royalty focused model gives you broad exposure to partners working on obesity and metabolic disease drugs at a time when the Novo Nordisk news has reminded investors how much single product risk can matter. Recent acquisitions such as XOMA Royalty have expanded the portfolio to more than 200 royalty assets. This increases diversification but also ties Ligand’s fortunes to partner execution and drug pricing trends. Analysts expect strong earnings and revenue growth, yet the stock trades well below one intrinsic value estimate and on a higher P/E than many peers, which points to both opportunity and valuation risk. The real question is how sustainable this royalty engine is as new metabolic and rare disease programs mature.

Ligand Pharmaceuticals’ expanding royalty stream and higher P/E suggest the market sees something powerful building, yet the story still feels only half told. Get the full context with the 3 key rewards and 1 important warning sign

Vertex Pharmaceuticals (VRTX)

Overview: Vertex Pharmaceuticals is a biotechnology company that focuses on treating serious diseases such as cystic fibrosis, sickle cell disease, beta thalassemia, acute pain and several kidney and metabolic disorders, selling its medicines globally to specialty pharmacies, wholesalers, hospitals and clinics.

Market Cap: US$121.3b

Vertex Pharmaceuticals provides exposure to the obesity and metabolic therapeutic area through its work on next generation weight loss and diabetes therapies, while still being anchored by a large cystic fibrosis franchise and newer products like CASGEVY and JOURNAVX. The company is investing heavily to build out kidney, endocrinology and autoimmune pillars, supported by the Crinetics acquisition and the AbCellera collaboration, which could broaden its reach beyond rare lung disease. At the same time, high drug prices, complex gene and cell therapy delivery, and rising competition in genetic medicine create pressure on margins and market share. A key consideration for investors is how Vertex manages those pressures relative to its current profitability metrics, return on equity and expanding pipeline.

Vertex Pharmaceuticals appears to be building multiple new treatment pillars while investors still focus on cystic fibrosis. To see how the current pipeline and profitability compare, go straight to the analysis report for Vertex Pharmaceuticals

The three stocks in this article are just the starting point. The full Healthcare, Obesity and Metabolic Disorder Therapeutics screener surfaces 11 more companies that carry equally compelling narratives and exposure to this theme through the Healthcare - Obesity and Metabolic Disorder Therapeutics screener. Use Simply Wall St to identify and analyze the specific catalysts, clinical pipelines and business models that matter to you so you can focus on the highest conviction opportunities in this space.

Take Control of Your Investment Journey

If Vertex Pharmaceuticals or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Do

Fresh breakout ideas do not stay under the radar for long. Once momentum is flying, ideal entry points get caught quickly. Check these curated lists and act now.

• Spot companies quietly building strong balance sheets before the crowd pays attention by scanning this curated list of solid balance sheet and fundamentals (49 results).
• Track fast moving infrastructure behind the AI boom so you are not chasing after prices have already jumped with the focused 55 AI infrastructure stocks.
• Consider potential momentum in specialist miners picked for quality and scale while they are still under the radar through the targeted 28 best rare earth metal stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.